Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1KD7U)

• Drug Name: ABI-011 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Lymphoma	2A80-2A86	Phase 1	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DM1KD7U

Molecule-Related Drug Atlas

Drug(s) Targeting DNA topoisomerase I (TOP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[4]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[4]
B-Lactams	DMR8YD6	Bacterial infection	1A00-1C4Z	Approved	[5]
Belotecan hydrocholoride	DM3SRJZ	Small-cell lung cancer	2C25.Y	Approved	[6]
Topetecan	DMAE6LK	Small-cell lung cancer	2C25.Y	Approved	[7]
Karenitecin	DMCRGY4	Lung cancer	2C25.0	Phase 3	[8]
Camptothecin	DM6CHNJ	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
Exatecan	DMCA7FN	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
Edotecarin	DM3ZL7D	Gastric adenocarcinoma	2B72	Phase 3	[11]
Rubitecan	DMDWU1S	Human immunodeficiency virus infection	1C62	Phase 3	[12]

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[13]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[14]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[15]
Ranibizumab	DMSYPNW	Central retinal vein occlusion with macular edema		Approved	[16]
Bevacizumab	DMSD1UN	Adenocarcinoma	2D40	Approved	[17]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[18]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[19]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[20]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[21]
Abicipar pegol	DM59OJ2	Diabetic macular edema	9B71.02	Phase 2	[22]

Drug(s) Targeting Angiogenesis (AGG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TRX-818	DMVGN42	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Drug(s) Targeting Tubulin beta (TUBB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vincristine	DMINOX3	Acute lymphoblastic leukaemia	2A85	Approved	[4]
Albendazole	DMYZ57N	Echinococcus granulosus infectious disease		Approved	[23]
Vindesine	DMVR628	Acute lymphoblastic leukaemia	2A85	Approved	[24]
Taxol	DMUOT9V	Breast cancer	2C60-2C65	Approved	[25]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[23]
Plinabulin	DMD7L48	Non-small-cell lung cancer	2C25.Y	Phase 3	[26]
Batabulin	DMHWE5R	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[27]
ABT-751	DMNG35S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[28]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[29]
BNC-105	DMJC8DR	Mesothelioma	2C51.2	Phase 2	[30]

Drug(s) Targeting Hepatocyte growth factor (HGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VM-202	DMSW80U	Angina pectoris	BA40	Phase 3	[31]
Donaperminogene seltoplasmid	DMH8IT5	Diabetic foot ulcer	BD54	Phase 3	[32]
ANG-3777	DMGP8WX	Delayed graft function	4B24.0	Phase 3	[33]
Ficlatuzumab	DMG65WH	Multiple myeloma	2A83	Phase 2	[1]
Collategene	DM27H0P	Peripheral Ischemic Ulcers	BD41	Phase 2	[34]
MP0250	DMR3VCY	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[1]
TAK-701	DML3M0O	Advanced malignancy	2A00-2F9Z	Phase 1	[35]
Rilotumumab	DMD8ZSW	Grade IV malignant glioma	2A00.0	Discontinued in Phase 2	[36]
N,O6-Disulfo-Glucosamine	DMYCV7U	Discovery agent	N.A.	Investigative	[37]
O2-Sulfo-Glucuronic Acid	DME78MS	Discovery agent	N.A.	Investigative	[37]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiogenesis (AGG)	TTB8Y9K	NOUNIPROTAC	Inhibitor	[1]
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Modulator	[3]
Hepatocyte growth factor (HGF)	TT4V2JM	HGF_HUMAN	Inhibitor	[1]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[3]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Inhibitor	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT01163071) A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
• [3] Company report (Indena)
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61.
• [6] Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43.
• [7] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [8] Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.
• [9] Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802.
• [10] Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70.
• [11] Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36.
• [12] Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [15] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [16] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [17] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [18] Clinical pipeline report, company report or official report of Genentech (2009).
• [19] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [20] Bispecific antibodies and their applications
• [21] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [22] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [23] Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
• [24] Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
• [25] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [26] NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
• [27] Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
• [28] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [29] Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
• [30] The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.
• [31] Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.
• [32] Clinical pipeline report, company report or official report of ViroMed.
• [33] Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury. Kidney Int Rep. 2020 Sep 25;5(12):2325-2332.
• [34] Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010 Sep;17(9):1152-61.
• [35] Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103.
• [36] Clinical pipeline report, company report or official report of Amgen (2009).
• [37] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.